Drug intelligence / Profile preview

UT-231B

Development stage: Phase 2
Lead developer: United Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

UT‑231B is an iminosugar small molecule that was under development by United Therapeutics Corporation as an oral drug for the treatment of hepatitis C virus (HCV). It acts as an alpha-glucosidase inhibitor. The drug completed acute and chronic Phase I dosing studies in early 2003 and entered a Phase II proof-of-concept study in patients with HCV who had failed conventional therapies. However, development appears to have been discontinued before approval[2][4][5].

Other names: (2R,3S,4R,5S)-1-(6-Ethoxyhexyl)-2-methyl-3,4,5-trihydroxypiperidine(2R,3S,4R,5S)-1-(6-Ethoxyhexyl)-2-methyl-3,4,5-trihydroxypiperidine tartrate324759-98-0912365-01-61001914-05-1UNII-MK831RYX9DUNII-MK-831RYX9DUNII-MK 831RYX9DUNII‑86R4PEJ40Z

Targets

GluI (Endoplasmic reticulum alpha-glucosidase I)

Beyond the preview

Go deeper on UT-231B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UT-231B.

Explore the full profile